PCLOF Stock Chart & Stats
$0.04
>-$0.01(-3.20%)
At close: 4:00 PM EDT
$0.04
>-$0.01(-3.20%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.12
Previous CloseN/A
Volume42.60K
Average Volume (3M)30.57K
Market Cap
$7.32M
Enterprise Value$31.59
Total Cash (Recent Filing)$77.50K
Total Debt (Recent Filing)$18.21M
Price to Earnings (P/E)―
Beta-1.96
Next Earnings
May 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding221,005,070
10 Day Avg. Volume25,287
30 Day Avg. Volume30,567
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe roughly 42% TTM revenue rebound indicates improving commercial activity and product demand after weaker periods. If sustained, higher sales can broaden operating scale, support customer development, and provide a stronger base for absorbing fixed costs over the next several quarters.
Gross Margin ImprovementGross margin expansion to approximately 37% suggests better pricing, product mix, and/or cost control. This improvement is an encouraging foundation for eventual profitability because each additional unit of revenue could contribute more toward operating expenses, provided the margin holds.
Ingredient-Focused B2B ModelThe B2B ingredient model gives PharmaCielo access to medical, wellness, and pharmaceutical-related applications without requiring it to sell only finished consumer products. Its focus on specified extracts and isolates can support repeat commercial use across regulated end markets.
Bears Say
Negative Equity And DebtNegative equity combined with a sizable debt load leaves the company with limited financial flexibility and a weak capital base. This can increase dependence on refinancing or new equity, potentially constraining investment capacity and creating dilution risk while losses continue.
Persistent Cash BurnMaterially negative operating and free cash flow means the business is not currently funding its operations internally. Persistent cash consumption can require external financing, limiting strategic flexibility and increasing liquidity risk if revenue or margins fail to improve enough.
Ongoing UnprofitabilityDespite stronger revenue and gross margin, the company remains far from break-even because operating costs still exceed its gross profit generation. Continued EBIT and net losses weaken retained capital, delay self-funding, and make the recovery dependent on further scale or cost reduction.
PharmaCielo News
PCLOF FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was <$0.01 and its highest was $0.12 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is $7.32M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is May 03, 2027 which is in 223 days.
How were PharmaCielo’s earnings last quarter?
PharmaCielo released its earnings results on Jul 29, 2026. The company reported -$0.005 earnings per share for the quarter.
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 221,005,070 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
PharmaCielo reported an EPS of -$0.005 in its last earnings report. Following the earnings report the stock price went down -9.524%.
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in PCLOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Ownership Overview
14.01% Insiders
0.14% Other Institutional Investors
85.72% Public Companies and
Individual Investors